Chronic stress level and functional health in older adults: the impact of fear of falling

Chronic stress level and functional health in older adults: the impact of fear of falling - FEARFALL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00029171

Enrollment

200

Registered

2022-07-28

Start date

2022-10-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fear of falling, sarcopenia

Interventions

Group 1: The intervention group will take part in a 4-month multicomponent exercise intervention. In the first four weeks of the intervention, training sessions will be provided twice weekly, with sup

Eligibility

Sex/Gender

All

Age

70 Years to 100 Years

Inclusion criteria

Inclusion criteria: - Age of 70 years or older - FES-I (16-item) score = 20 - Ability to come to the study center without help - Ability and willingness to provide informed consent and accept randomization to either study arm

Exclusion criteria

Exclusion criteria: - Life expectancy of less than 12 months - Participation in another intervention trial (physical exercise or medical) at the same time or within the previous 6 months - Anti-inflammatory drugs (e.g. glucocorticoids, permanent prescribed NSAIDs) - Cognitive impairment (Mini-Mental-Status-Examination [MMSE] < 24 points) - Any medical, psychiatric, or behavioral factors that in the judgment of the principal investigator may interfere with the study participation or the ability to follow the intervention

Design outcomes

Primary

Measure	Time frame
Decrease in fall-related psychological concerns at T1 (after the intervention) by FES-I score in comparison to control group	—

Secondary

Measure	Time frame
All secondary outcome meseaures will be assessed at all time points (T0, T1 and T2): sarcopenia (BIA) physical function (SPPB, handgrip strength) health-related quality of life (EQ-5D+Vas) physical activity (Actigraphy) cognitive function (MMSE, TMT A+B) general psychological status (GDS, PSS, GAS) stress system activity (salivary cortsiol, alpha amylase) systemic inflammation (CRP, IL-6, TNF-alpha, IL-10) intracellular inflammatory activity (gene expression IL-1beta, IL-6, IL-10 and I-kappa B)	—

Measure

Time frame

All secondary outcome meseaures will be assessed at all time points (T0, T1 and T2): sarcopenia (BIA) physical function (SPPB, handgrip strength) health-related quality of life (EQ-5D+Vas) physical activity (Actigraphy) cognitive function (MMSE, TMT A+B) general psychological status (GDS, PSS, GAS) stress system activity (salivary cortsiol, alpha amylase) systemic inflammation (CRP, IL-6, TNF-alpha, IL-10) intracellular inflammatory activity (gene expression IL-1beta, IL-6, IL-10 and I-kappa B)

—

Countries

Germany

Contacts

Public ContactSusanne Muck

Institut für Biomedizin des Alterns Friedrich-Alexander-Universität Erlangen-Nürnberg

susanne.muck@fau.de+49 911 5302 96156

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 24, 2026